Zymeworks (NASDAQ:ZYME) said it has achieved a $14M cash research milestone through its collaboration with GSK (GSK). Under ...

Harbour BioMed's subsidiary inks $395M deal, ORIC plans Phase 3 trials, Idorsia updates on deals, Sanofi backs Enveda, Zymeworks gets GSK milestone, BerGenBio ends study, Ignota raises £5.5M ...

Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a ...

Leerink Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and present on March 10 at 8:00 am ET in Miami, FL. Barclays 27 th Annual Global Healthcare ...

Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms ...

Zymeworks Inc: Navigating Market Sentiment, Insider Dynamics, and Institutional Confidence ...

VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology ...

VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...